Project Grant HT94252410072
Award Date
2/15/24
Completion Date
2/14/27
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The federal Project Grant award of $1,477,615.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports comparative transcriptomic and proteomic profiling of full-length androgen receptor (AR) and AR-V7 splice variant condensates in prostate cancer. This research, conducted by the University of British Columbia, aims to transform healthcare for military service members, veterans, and the broader public through innovative and...
This federal Project Grant award of $426,154 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of British Columbia (UBC) to investigate immunological landscapes in neuroendocrine prostate cancer. The goal is to develop strategies for enhancing the efficacy of immunotherapy. UBC, a prominent public research university in Canada, will leverage its advanced research capabilities and expertise in...
The University of British Columbia (UBC), through its Research Services division, has been awarded a $407,599 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 2-year research project titled "Epigenetic and Metabolomics Vulnerabilities in ASCL1-Driven NEPC Subtype" starting on September 1, 2024. This grant allows UBC researchers to leverage their expertise in biomedical research to...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The University of British Columbia received a $1,259,331 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2024 targeting a non-oncogene addiction to the autocrine SEMA3C growth pathway for the treatment of lethal metastatic prostate cancer. A portion of the work involving confirming AR-V7 regulation of SEMA3C expression and...
The University of British Columbia (UBC) received a $507,035 Project Grant award from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420). The grant, awarded on September 1, 2023, will fund research for "The Ovarian Cancer Observatory: Prevention, Impact, and Learning from Opportunistic Salpingectomy" over a 4-year period through August 31, 2027. As the prime grantee, UBC will leverage its expertise in medical research and data analysis...
The U.S. Defense Health Agency awarded a $399,816 Project Grant to The University of British Columbia (UBC) for the project "ENGINEERING NEXT-GENERATION SELF-AMPLIFYING RNA THERAPEUTICS ENCODING BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES FOR TREATMENT OF OVARIAN CANCER." The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports UBC's research to develop innovative self-amplifying RNA-based therapies encoding bispecific T-cell engager...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The University of British Columbia was awarded a $2,498,328 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on using blood biomarkers to improve diagnosis of brain injury and assess dementia risk in survivors of intimate partner violence. The 4-year grant, awarded on June 1, 2024, will enable UBC researchers to leverage their expertise in biomedical research, clinical trials, and data analysis to...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...